Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT02576301
Title	Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS
Acronym	AML
Recruitment	Unknown status
Gender	both
Phase	Phase Ib/II
Variant Requirements	No
Sponsors	OXiGENE
Indications	acute myeloid leukemia myelodysplastic syndrome
Therapies	Combretastatin A1 Diphosphate Combretastatin A1 Diphosphate + Cytarabine
Age Groups:	adult
Covered Countries	USA

Filter rows:

Showing 1 to 4 of 4 entries

Facility	Status	City	State	Zip	Country	Details
David Geffen School of Medicine at UCLA	RECRUITING	Los Angeles	California	90095	United States	Details
University of Florida	RECRUITING	Gainesville	Florida	32610	United States	Details
University of Kansas Cancer Center and Medical Pavilion	RECRUITING	Westwood	Kansas	66205	United States	Details
University of Miami Sylvester Comprehensive Cancer Center	RECRUITING	Miami	Florida	33136	United States	Details

Showing 1 to 4 of 4 entries

Filter rows:

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field